STEMCELLS INC Form 8-K July 22, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):	July 18, 2014
---	---------------

StemCells, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-19871	94-3078125
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employe Identification No
7707 Gateway Blvd, Suite 140, Newark, California		94560
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including are	ea code:	510.456.4000
	Not Applicable	
Former name	or former address, if changed since l	ast report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
ſ	1	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: STEMCELLS INC - Form 8-K

<u>Top of the Form</u> Item 8.01 Other Events.

On July 18, 2014, StemCells, Inc. (the "Company") announced the initial closing of a common stock and short term warrants offering (the "Offering") and the sale of 11,299,435 registered shares of the Company's Common Stock to two investors. The terms of the Offering are described in the Company's Form 8-K filed on July 15, 2014.

The Company's press release announcing the initial closing of the Offering is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 Press Release dated July 18, 2014 announcing the closing of a \$20 million offering

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

StemCells, Inc.

July 21, 2014 By: /s/ Kenneth Stratton

Name: Kenneth Stratton Title: General Counsel

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Press release dated July 18, 2014